What is the initial dosage of atomoxetine (Strattera) for children, adolescents, and adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Initial Dosage of Atomoxetine (Strattera) for ADHD

The initial dosage of atomoxetine for children and adolescents up to 70 kg is 0.5 mg/kg/day, while for adults and children over 70 kg, the initial dose is 40 mg/day. 1

Dosing Guidelines by Age Group

Children and Adolescents (≤70 kg)

  • Starting dose: 0.5 mg/kg/day 2, 1
  • Target dose: Increase after a minimum of 3 days to approximately 1.2 mg/kg/day 1
  • Maximum dose: 1.4 mg/kg/day or 100 mg/day, whichever is less 2, 1
  • Administration: Can be given as a single morning dose or divided into morning and late afternoon doses 1

Adults and Children >70 kg

  • Starting dose: 40 mg/day 3, 1
  • Target dose: Increase after a minimum of 3 days to approximately 80 mg/day 1
  • Maximum dose: 100 mg/day 2, 1
  • Administration: Can be given as a single morning dose or divided into morning and late afternoon doses 1

Dosing Adjustments for Special Populations

CYP2D6 Poor Metabolizers or Patients Taking CYP2D6 Inhibitors

  • Children and adolescents ≤70 kg: Start at 0.5 mg/kg/day and only increase to the target dose of 1.2 mg/kg/day if symptoms don't improve after 4 weeks 1
  • Adults and children >70 kg: Start at 40 mg/day and only increase to the target dose of 80 mg/day if symptoms don't improve after 4 weeks 1

Hepatic Impairment

  • Moderate impairment (Child-Pugh Class B): Reduce initial and target doses to 50% of normal dose 1
  • Severe impairment (Child-Pugh Class C): Reduce initial and target doses to 25% of normal dose 1

Efficacy and Dose-Response Relationship

Research has demonstrated a graded dose-response relationship with atomoxetine, with 1.2 mg/kg/day showing superior efficacy compared to lower doses 4. Studies have shown that:

  • 1.2 mg/kg/day and 1.8 mg/kg/day doses show similar efficacy outcomes, suggesting 1.2 mg/kg/day is the appropriate initial target dose for most patients 4
  • No additional benefit has been demonstrated for doses higher than 1.2 mg/kg/day 1
  • For maintenance treatment after achieving a robust response, a lower dose of 0.5 mg/kg/day may be effective for some patients 5

Administration Considerations

  • Atomoxetine can be taken with or without food 1
  • Capsules should be taken whole, not opened 1
  • No tapering is required when discontinuing atomoxetine 1
  • Dose adjustments should be made at intervals of no less than 3 days 1

Safety Monitoring

  • Screen for bipolar disorder prior to starting atomoxetine 1
  • Monitor for suicidal ideation, particularly in children and adolescents during the first few months of treatment 2
  • Be aware of potential cardiovascular effects including modest increases in heart rate and blood pressure 6
  • Common side effects include nausea, vomiting, fatigue, decreased appetite, abdominal pain, and somnolence 2, 6

Clinical Pearls

  • Atomoxetine is not a controlled substance and has negligible abuse potential, making it suitable for patients with substance use concerns 7
  • Full therapeutic effect may take several weeks to develop, unlike stimulants which often work immediately
  • Once-daily dosing is possible and may improve medication adherence 3
  • Atomoxetine may be particularly useful for patients with comorbid anxiety or tics 3

Following these dosing guidelines will help optimize the therapeutic benefits of atomoxetine while minimizing potential adverse effects in the treatment of ADHD.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.